FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992215482> ?p ?o ?g. }

• W1992215482 endingPage "649" @default.
• W1992215482 startingPage "634" @default.
• W1992215482 abstract "Proporre protocolli di gestione odontoiatrica per il paziente che assume o che assumerà farmaci (per esempio bisfosfonati, denosumab e anti-angiogenetici) correlati all’insorgenza di osteonecrosi dei mascellari (OsteoNecrosis of the Jaws, ONJ). Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Società Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Società Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinicoterapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni scientifiche disponibili in merito alla ONJ (associata all’assunzione sia di bisfosfonati sia di denosumab e/o anti-angiogenetici) in rapporto con le procedure odontoiatriche. La ONJ da bisfosfonati, ma anche, negli ultimi anni, da denosumab e anti-angiogenetici, si può considerare la più emergente delle patologie odontoiatriche severe: negli ultimi 10 anni si sono registrati migliaia di casi in letteratura, con importanti implicazioni sulla qualità di vita del paziente. La comunità medica e odontoiatrica ha percepito la severità della patologia, ma anche la necessità di darsi regole, di ridisegnare il percorso preventivo e assistenziale di tale malattia: in tutte le nazioni industrializzate e parimenti in Italia sono state stilate linee guida o raccomandazioni per la prevenzione e cura della ONJ, malattia inizialmente solo associata ai bisfosfonati per via endovenosa, in pazienti oncologici, ma poi rilevata, sebbene con frequenza inferiore, anche nei pazienti non oncologici, principalmente osteoporotici, in terapia con bisfosfonati. Al fine di ridurre il rischio di ONJ, il ruolo dell’odontoiatra è fondamentale: dall’eliminazione dei fattori di rischio locali noti all’applicazione dei protocolli di gestione odontoiatrica, alla scelta del timing dell’azione odontoiatrica, sia per il paziente oncologico (prima, durante e dopo il trattamento con bisfosfonati in combinazione o non in combinazione con anti-angiogenetici o con denosumab) sia per il paziente non oncologico (prima, durante e dopo il trattamento con bisfosfonati). Specific protocols are suggested for the dental management of patients taking bisphosphonates, denosumab or antiangiogenic agents so as to reduce the risk of osteonecrosis of the jaw (ONJ). The authors, directly involved with the recent publication of the Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione, endorsed by Società Italiana di Chirurgia Maxillo-Facciale (SICMF) and Società Italiana di Patologia e Medicina Orale (SIPMO), survey and discuss the dental management of patients taking bone modifiers and/or anti-angiogenic agents at risk of ONJ, on the basis of available scientific information. ONJ should be considered the most emerging disease that affects the oral cavity; ONJ is mainly due to bisphosphonates, but it has been also associated with denosumab and anti-angiogenic agents in recent years. Thousands of cases have been reported in the scientific literature so far, with important implications for the National Health Systems. ONJ can heavily impact on patients’ quality of life. In all industrialized nations and in Italy too, guidelines or recommendations for the prevention and treatment of ONJ have been drafted. In the beginning, these documents were centred on the care of cancer patients taking intravenous bisphosphonates, but soon after they were upgraded to include the less-frequent ONJ in non-cancer patients taking bisphosphonates. To reduce the occurrence of ONJ in patients at risk, the role of the dentist is crucial in the effort to eliminate the known local risk factors applying specific dental treatment protocols, wherever indicated, and select the proper timing to deliver such treatments, both in cancer and non-cancer patients." @default.
• W1992215482 created "2016-06-24" @default.
• W1992215482 creator A5025486771 @default.
• W1992215482 creator A5037536356 @default.
• W1992215482 creator A5053084731 @default.
• W1992215482 creator A5059694955 @default.
• W1992215482 creator A5062414404 @default.
• W1992215482 creator A5067216676 @default.
• W1992215482 date "2013-12-01" @default.
• W1992215482 modified "2023-09-25" @default.
• W1992215482 title "Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: prevenzione dentale e sicurezza dei trattamenti odontoiatrici" @default.
• W1992215482 cites W1523677790 @default.
• W1992215482 cites W154536858 @default.
• W1992215482 cites W1850927048 @default.
• W1992215482 cites W1901352575 @default.
• W1992215482 cites W1928403104 @default.
• W1992215482 cites W1966145120 @default.
• W1992215482 cites W1971534684 @default.
• W1992215482 cites W1977488653 @default.
• W1992215482 cites W1988968838 @default.
• W1992215482 cites W1989040196 @default.
• W1992215482 cites W1989627049 @default.
• W1992215482 cites W1990119475 @default.
• W1992215482 cites W1993479864 @default.
• W1992215482 cites W1997286830 @default.
• W1992215482 cites W1997523719 @default.
• W1992215482 cites W2001115065 @default.
• W1992215482 cites W2015338398 @default.
• W1992215482 cites W2015483212 @default.
• W1992215482 cites W2017845136 @default.
• W1992215482 cites W2023350358 @default.
• W1992215482 cites W2028628152 @default.
• W1992215482 cites W2043018502 @default.
• W1992215482 cites W2044894401 @default.
• W1992215482 cites W2045863657 @default.
• W1992215482 cites W2047367641 @default.
• W1992215482 cites W2047819433 @default.
• W1992215482 cites W2055635018 @default.
• W1992215482 cites W2071488615 @default.
• W1992215482 cites W2072022812 @default.
• W1992215482 cites W2073821954 @default.
• W1992215482 cites W2078977969 @default.
• W1992215482 cites W2084052943 @default.
• W1992215482 cites W2087614588 @default.
• W1992215482 cites W2091705733 @default.
• W1992215482 cites W2093031463 @default.
• W1992215482 cites W2102285316 @default.
• W1992215482 cites W2107135867 @default.
• W1992215482 cites W2110604509 @default.
• W1992215482 cites W2119436365 @default.
• W1992215482 cites W2122972229 @default.
• W1992215482 cites W2129750045 @default.
• W1992215482 cites W2133042961 @default.
• W1992215482 cites W2136646477 @default.
• W1992215482 cites W2137302084 @default.
• W1992215482 cites W2138811642 @default.
• W1992215482 cites W2143254775 @default.
• W1992215482 cites W2151212373 @default.
• W1992215482 cites W2152287518 @default.
• W1992215482 cites W2154182011 @default.
• W1992215482 cites W2163852287 @default.
• W1992215482 cites W2165198475 @default.
• W1992215482 cites W2165355371 @default.
• W1992215482 cites W2165840608 @default.
• W1992215482 cites W2170387124 @default.
• W1992215482 cites W2181692038 @default.
• W1992215482 cites W2181739949 @default.
• W1992215482 cites W2286004972 @default.
• W1992215482 cites W2412434670 @default.
• W1992215482 cites W2417594390 @default.
• W1992215482 cites W2594596381 @default.
• W1992215482 cites W32740176 @default.
• W1992215482 cites W1982020888 @default.
• W1992215482 doi "https://doi.org/10.1016/s0011-8524(13)70110-7" @default.
• W1992215482 hasPublicationYear "2013" @default.
• W1992215482 type Work @default.
• W1992215482 sameAs 1992215482 @default.
• W1992215482 citedByCount "0" @default.
• W1992215482 crossrefType "journal-article" @default.
• W1992215482 hasAuthorship W1992215482A5025486771 @default.
• W1992215482 hasAuthorship W1992215482A5037536356 @default.
• W1992215482 hasAuthorship W1992215482A5053084731 @default.
• W1992215482 hasAuthorship W1992215482A5059694955 @default.
• W1992215482 hasAuthorship W1992215482A5062414404 @default.
• W1992215482 hasAuthorship W1992215482A5067216676 @default.
• W1992215482 hasBestOaLocation W19922154822 @default.
• W1992215482 hasConcept C134018914 @default.
• W1992215482 hasConcept C142362112 @default.
• W1992215482 hasConcept C15708023 @default.
• W1992215482 hasConcept C2776286101 @default.
• W1992215482 hasConcept C2776541429 @default.
• W1992215482 hasConcept C71924100 @default.
• W1992215482 hasConceptScore W1992215482C134018914 @default.
• W1992215482 hasConceptScore W1992215482C142362112 @default.
• W1992215482 hasConceptScore W1992215482C15708023 @default.
• W1992215482 hasConceptScore W1992215482C2776286101 @default.
• W1992215482 hasConceptScore W1992215482C2776541429 @default.
• W1992215482 hasConceptScore W1992215482C71924100 @default.

• next